Literature DB >> 26119837

The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions.

Jeffrey K Aronson1, Robin E Ferner2,3.   

Abstract

BACKGROUND: Adverse drug reactions are sometimes described as being 'non-dose-related' because no relationship has been found between increasing doses and either the intensity of the response or the proportion of individuals in whom the response occurs; furthermore, hypersensitivity reactions are often regarded as being non-dose-related, even if different doses have not been studied. However, the law of mass action implies that all pharmacological effects are concentration related and should increase in intensity with increasing dose. We set out to explain this paradox.
METHODS: We searched for published adverse drug reactions that have been described as non-dose-related and analysed them.
RESULTS: We identified four categories of explanations that resolve the paradox: (i) the reaction is not real; it may have occurred by chance or there may be methodological problems, such as bias or confounding factors; (ii) the dose-response curve for the adverse effect reaches a maximum at doses lower than were studied (i.e. a hypersusceptibility reaction); this underpins the use of test doses to predict the possibility of an adverse reaction at therapeutic doses; (iii) susceptibility to the adverse reaction differs widely among individuals; and (iv) imprecision or inaccuracy in the measurement of either dose or effect obscures dose responsiveness. This last explanation encompasses: (a) reactions related to cumulative dose; (b) dissociation between dose and concentration through saturable pharmacokinetics; and (c) variability in the measurement of the effect. CONCLUSIONS AND IMPLICATIONS: If an adverse drug reaction appears to be non-dose-related, the reasons should be sought, having these mechanisms in mind.
© 2015 The British Pharmacological Society.

Entities:  

Keywords:  dose-response relationship; drug-related adverse effects; drug-related adverse reactions; law of mass action

Mesh:

Year:  2015        PMID: 26119837      PMCID: PMC4693576          DOI: 10.1111/bcp.12706

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

Review 1.  Cephalosporin allergy.

Authors:  P S Kelkar; J T Li
Journal:  N Engl J Med       Date:  2001-09-13       Impact factor: 91.245

2.  A modification of receptor theory.

Authors:  R P STEPHENSON
Journal:  Br J Pharmacol Chemother       Date:  1956-12

3.  An Investigation of the Laws of Disinfection.

Authors:  H Chick
Journal:  J Hyg (Lond)       Date:  1908-01

4.  Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 5.  The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview.

Authors:  Edward J Calabrese; Robyn Blain
Journal:  Toxicol Appl Pharmacol       Date:  2005-02-01       Impact factor: 4.219

Review 6.  A strategy for regulatory action when new adverse effects of a licensed product emerge.

Authors:  Jeffrey K Aronson; Deirdre Price; Robin E Ferner
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Quantitative relationships between sensitizing dose of DNCB and reactivity in normal subjects.

Authors:  P S Friedmann; C Moss; S Shuster; J M Simpson
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

8.  Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

Authors:  Nazzareno Galiè; Horst Olschewski; Ronald J Oudiz; Fernando Torres; Adaani Frost; Hossein A Ghofrani; David B Badesch; Michael D McGoon; Vallerie V McLaughlin; Ellen B Roecker; Michael J Gerber; Christopher Dufton; Brian L Wiens; Lewis J Rubin
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

9.  Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.

Authors:  C LaForce; M Alexander; R Deckelmann; L M Fabbri; Z Aisanov; R Cameron; R Owen; M Higgins
Journal:  Allergy       Date:  2008-01       Impact factor: 13.146

10.  Safety of indacaterol in the treatment of patients with COPD.

Authors:  James F Donohue; Dave Singh; Oliver Kornmann; David Lawrence; Cheryl Lassen; Benjamin Kramer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-09-22
View more
  11 in total

1.  Classifying ADRs--does dose matter?

Authors:  Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2015-11-02       Impact factor: 4.335

Review 2.  The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

Review 3.  Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2015-10-22       Impact factor: 4.335

Review 4.  Susceptibility to adverse drug reactions.

Authors:  Robin Ferner; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2019-07-17       Impact factor: 4.335

Review 5.  Pharmacogenomics of off-target adverse drug reactions.

Authors:  Sarah L Garon; Rebecca K Pavlos; Katie D White; Nancy J Brown; Cosby A Stone; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2017-04-27       Impact factor: 4.335

6.  Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles.

Authors:  Sue Jordan; Patricia A Logan; Gerwyn Panes; Mojtaba Vaismoradi; David Hughes
Journal:  Pharmacy (Basel)       Date:  2018-09-18

7.  New Insights in Computational Methods for Pharmacovigilance: E-Synthesis, a Bayesian Framework for Causal Assessment.

Authors:  Francesco De Pretis; Barbara Osimani
Journal:  Int J Environ Res Public Health       Date:  2019-06-24       Impact factor: 3.390

8.  Nobody ever questions-Polypharmacy in care homes: A mixed methods evaluation of a multidisciplinary medicines optimisation initiative.

Authors:  Sue Jordan; Hayley Prout; Neil Carter; John Dicomidis; Jamie Hayes; Jeffrey Round; Andrew Carson-Stevens
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

9.  Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1.

Authors:  Zhongya Ni; Chao Yao; Xiaowen Zhu; Chenyuan Gong; Zihang Xu; Lixin Wang; Suyun Li; Chunpu Zou; Shiguo Zhu
Journal:  Br J Cancer       Date:  2017-10-12       Impact factor: 7.640

10.  A web resource for mining HLA associations with adverse drug reactions: HLA-ADR.

Authors:  Gurpreet S Ghattaoraya; Yenal Dundar; Faviel F González-Galarza; Maria Helena Thomaz Maia; Eduardo José Melo Santos; Andréa Luciana Soares da Silva; Antony McCabe; Derek Middleton; Ana Alfirevic; Rumona Dickson; Andrew R Jones
Journal:  Database (Oxford)       Date:  2016-05-17       Impact factor: 3.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.